

SGX943 – Key References

Presentations:

Donini O. Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease. Presentation at the 2017 Drug Discovery and Therapy World Congress Meeting. **July 10-13, 2017.**



[View PDF file online](#)
[View presentation on YouTube](#)

Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. **March 20-21, 2017.**



[View PDF file online](#)
[View presentation on YouTube](#)

Donini O, Straube R. SGX942 Reduces the Duration of Severe Oral Mucositis. Presentation at 2016 Multinational Association for Supportive Care in Cancer Conference. **June 23-25, 2016**



[View PDF file online](#)

Donini O, Morici L. Innate Defense Regulators as Treatment for Melioidosis. Presentation at 2015 ASM Biodefense and Emerging Diseases Research Meeting. **February 9-11, 2015.**



[View PDF file online](#)

Donini, O. Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection. Presentation at BARDA TechWatch Meeting. **August 2016.**



[View PDF file online](#)

Papers:

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. *Biotech Reports*. 2017; 15:24-26.



[View PDF file online](#)

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. *J Biotech* **2016**; 239: 115-125.



[View link online](#)

North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici L, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. *J Biotech* **2016**; 226: 24-34.



[View link online](#)

Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y, Donini O, Guarna MM, Finlay BF, North JR, Hancock REW. An anti-infective peptide that selectively modulates the innate immune response. *Nat Biotechnol* 2007;25: 465-72.



[View link online](#)

Yu HB, Kielczewska A, Rozek A, Takenaka S, Li Y, Thorson L, et al. Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. *J Biol Chem*. 2009;284,36007-11.



[View link online](#)

Athman R, Philpott D. 2004. Innate immunity via Toll-like receptors and Nod proteins. *Curr Opin Microbiol* 7: 25-32

Beutler B. 2004. Innate immunity: an overview. *Mol Immunol* 40: 845-59

Beutler B, Hoebe K, Du X, Ulevitch RJ. 2003. How we detect microbes and respond to them: the Toll-like receptors and their transducers. *J Leukoc Biol* 74: 479-85

CDC: Centers for Disease Control and Prevention. 2012. Melioidosis - risk of exposure. Accessed March 26, 2013; <http://www.cdc.gov/melioidosis/exposure/index.html>

Chaowagul W, Chierakul W, Simpson AJ, Short JM, Stepniewska K, et al. 2005. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. *Antimicrob Agents Chemother* 49: 4020-5

Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. *Clin Microbiol Rev* 18: 383-416

Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Wuthiekanun V, et al. 2007. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. *Clin Infect Dis* 45: 308-14

Currie, B. J., D. A. Fisher, D. M. Howard, J. N. Burrow, S. Selvanayagam, P. L. Snelling, N. M. Anstey, and M. J. Mayo. 2000. The epidemiology of melioidosis in Australia and Papua New Guinea. *Acta Trop* 74:121-127.

- Doyle SL, O'Neill LA. 2006. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. *Biochem Pharmacol* 72: 1102-13
- Dupont N, Lafont F. 2009. How autophagy regulates the host cell signaling associated with the postpartum bacteria cocoon experienced as a danger signal. *Autophagy* 5: 1222-3
- Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ. 2007. A critical role for neutrophils in resistance to experimental infection with *Burkholderia pseudomallei*. *J Infect Dis* 195: 99-107
- Egan AM, Gordon DL. 1996. *Burkholderia pseudomallei* activates complement and is ingested but not killed by polymorphonuclear leukocytes. *Infect Immun* 64: 4952-9
- Foster SL, Hargreaves DC, Medzhitov R. 2007. Gene-specific control of inflammation by TLR-induced chromatin modifications. *Nature* 447: 972-8
- Galyov EE, Brett PJ, DeShazer D. 2010. Molecular insights into *Burkholderia pseudomallei* and *Burkholderia mallei* pathogenesis. *Annu Rev Microbiol* 64: 495-517
- Geetha T and Wooten MW. 2002. Structure and functional properties of the ubiquitin binding protein p62. *FEBS Leters* 512: 19-24
- Haque A, Easton A, Smith D, O'Garra A, Van Rooijen N, et al. 2006. Role of T cells in innate and adaptive immunity against murine *Burkholderia pseudomallei* infection. *J Infect Dis* 193: 370-9
- Harley VS, Dance DA, Tovey G, McCrossan MV, Drasar BS. 1998. An ultrastructural study of the phagocytosis of *Burkholderia pseudomallei*. *Microbios* 94: 35-45
- Inglis, TJJ., O'Reilly, L., Merritt, A. J., Levy, A., Heath, C. 2011. The Aftermath of the Western Australian Melioidosis Outbreak. *Am J Trop Med Hyg* 84(6): 851–857.
- Into T, Inomata M, Niida S, Murakami Y, Shibata K. 2010. Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by sequestosome 1 and histone deacetylase 6. *J Biol Chem* 285: 35759-69
- Janeway CA, Jr., Medzhitov R. 2002. Innate immune recognition. *Annu Rev Immunol* 20: 197-216
- Jones AL, Beveridge TJ, Woods DE. 1996. Intracellular survival of *Burkholderia pseudomallei*. *Infect Immun* 64: 782-90
- Kim JY, Ozato K. 2009. The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. *J Immunol* 182: 2131-40
- Lackner C, Dlaska D, Fuchsbichler A, Stumptner C, Gogg-Kamerer, et al. 2005. p62 protein is expressed in pancreatic β cells. *J Pathol* 206: 402–408

- Ma, G., D. Zheng, Q. Cai, and Z. Yuan. 2010. Prevalence of *Burkholderia pseudomallei* in Guangxi, China. *Epidemiology and Infection* 138:37-39
- Matzinger P. 2002a. The danger model: a renewed sense of self. *Science* 296: 301-5
- Matzinger P. 2002b. An innate sense of danger. *Ann N Y Acad Sci* 961: 341-2
- Miyagi K, Kawakami K, Saito A. 1997. Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against *Burkholderia pseudomallei*. *Infect Immun* 65: 4108-13
- Moscat J, Diaz-Meco MT. 2009. p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell* 137: 1001-4
- Moscat J, Diaz-Meco MT, Wooten MW. 2007. Signal integration and diversification through the p62 scaffold protein. *Trends Biochem Sci* 32: 95-100
- Peacock, S. J., D. Limmathurotsakul, Y. Lubell, G. C. Koh, L. J. White, N. P. Day, and R. W. Titball. 2012. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. *PLoS Negl Trop Dis* 6:e1488.
- Pruksachartvuthi S, Aswapokee N, Thankerngpol K. 1990. Survival of *Pseudomonas pseudomallei* in human phagocytes. *J Med Microbiol* 31: 109-14
- Rodriguez A, Duran A, Selloum M, Chanmpy M-F, Diez-Guerra FJ et al. 2006. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. *Cell Metab* 3:211-222
- Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ. 1999. Obligatory role of gamma interferon for host survival in a murine model of infection with *Burkholderia pseudomallei*. *Infect Immun* 67: 3593-600
- Seibenhener ML, Geetha T, Wooten MW. 2007. Sequestosome 1/p62--more than just a scaffold. *FEBS Lett* 581: 175-9
- Tangsudjai S, Pudla M, Limposuwan K, Woods DE, Sirisinha S, Utaisincharoen P. 2010. Involvement of the MyD88-independent pathway in controlling the intracellular fate of *Burkholderia pseudomallei* infection in the mouse macrophage cell line RAW 264.7. *Microbiol Immunol* 54: 282-90
- Tosi MF. 2005. Innate immune responses to infection. *J Allergy Clin Immunol* 116: 241-9; quiz 50
- U.S. Department of Health and Human Services. 2012. 2012 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy.
<http://www.phe.gov/Preparedness/mcm/phecce/Documents/2012-PHEMCE-Strategy.pdf>

Utainsincharoen P, Arjcharoen S, Lengwehasatit I, Limposuwan K, Sirisinha S. 2005. Burkholderia pseudomallei invasion and activation of epithelial cells requires activation of p38 mitogen-activated protein kinase. Microb Pathog 38: 107-12

Vidyalakshmi, K., Shrikala B., Bharathi B., Suchitra U. 2007. Melioidosis: an under-diagnosed entity in western coastal india: a clinico-microbiological analysis. Indian Journal of Medical Microbiology 25(3): 245-8

White NJ. 2003. Melioidosis. Lancet 361: 1715-22

Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 4: 272-82

Wiersinga WJ, Wieland CW, Roelofs JJ, van der Poll T. 2008. MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei. PLoS One 3: e3494

Wuthiekanun, V., S. J. Peacock. 2006. Management of Melioidosis. Expert Rev Anti Infect Ther 4: 445-455

Yoshikawa Y, Ogawa M, Hain T, Yoshida M, Fukumatsu M, et al. 2009. Listeria monocytogenes ActA-mediated escape from autophagic recognition. Nat Cell Biol 11: 1233-40

Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, Brumell JH. 2009. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. J Immunol 183: 5909-16

Posters:

Donini O, Straube R. Host-Directed Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance. Poster presented at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. **2018**.



[View PDF file online](#)

Donini O, Straube R. Host-Directed Innate Defense Regulators with Preclinical and Clinical Proof of Concept. Poster presented at the 2018 American Society of Microbiology Microbe Conference. **2018**.



[View PDF file online](#)

Donini O, Behrens E, Haulenbeek A, Pullion C, Schaber C. An Innate Defense Regulator for the Treatment of Macrophage Activation Syndrome: Preclinical Studies in an Orphan Indication. Poster Presented at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit. **2016**.



[View PDF file online](#)

Donini O, Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Elder J. SGX942 Reduces the Duration of Severe Oral Mucositis. Poster presented at the 25th Multinational Association of Supportive Care in Cancer. **2016**.



[View PDF file online](#)

Takenaka S, Rozek A, Kielczewska A, Thorson L, North JR, Finlay BB, Donini O. Innate Defense Regulators are a novel macrophage-mediated therapy to treat infectious and inflammatory diseases. Poster presentation at Keystone Symposium on The Macrophage: The intersection of Pathogenic & Protective Inflammation. **2010**.



[View PDF file online](#)

Kielczewska A, Yu HB, Rozek A, Takenaka S, Li Y, Guarna MM, North JR, Foster LJ, Finlay BB, Donini O. Sequestosome-1 / p62 is the key intracellular target of innate defense regulator peptide. Poster presentation at Keystone Symposium on The Macrophage: The intersection of Pathogenic & Protective Inflammation. **2010**.



[View PDF file online](#)

Donini O, Watkins BA, Palardy J, Opal S, Sonis S, Abrams MJ, North JR. Reduced Infection and Mucositis in Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate. 2010. Blood (ASH Annual Meeting Abstracts) **2010**; 116:3781.



[View PDF file online](#)

Yu H, Kielczewska A, Rozek A, Takenaka S, Li Y, Guarna M, Thorson L, Hancock R, North J, Foster L, Donini O, Finlay B. SQSTM-1/p62: A Novel Therapeutic Target in Infectious and Inflammatory Disease. Poster Presentation at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. **2009**.



[View PDF file online](#)